AI Article Synopsis
- Genotype 4 Hepatitis C virus accounts for about 20% of global infections and poses a significant healthcare challenge.
- Previous studies indicate that interferon can lower the risk of developing hepatocellular carcinoma in chronic hepatitis C patients.
- This report discusses two cases of hepatocellular carcinoma in patients with genotype 4, highlighting potential oncogenic effects and the need for long-term monitoring even without cirrhosis.
Article Abstract
Genotype 4 Hepatitis C virus represents approximately 20% of global Hepatitis C virus infection and is the source of a considerable burden to health-care providers across the globe. Many studies reported that interferon reduces the risk of hepatocellular carcinoma in patients with chronic hepatitis C.Hereby, we are reporting two cases of hepatocellular carcinoma in Hepatitis C virus-genotype 4 after complete viral eradication and in absence of cirrhosis. We aim to highlight the possible direct oncogenic effect of Hepatitis C virus-genotype 4, particularly with concomitant bilharzial infection and the importance of life-log follow up of these patients even in absence of cirrhosis.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2827147 | PMC |
| http://dx.doi.org/10.1186/1757-1626-0002-0000007927 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!